| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
DPPG sodium does not have a specific biological receptor target. As an anionic phospholipid, it functions as a structural component of liposomes and artificial membranes. It has been reported to inhibit cowpox virus infection as a surfactant.
|
|---|---|
| ln Vitro |
In vitro, DPPG sodium is used to prepare micelles, liposomes, and other types of artificial membranes. As a surfactant, it has been shown to inhibit cowpox virus infection in cell-based assays.
|
| ln Vivo |
In vivo, DPPG sodium-containing liposomes and artificial membranes are used for drug delivery and membrane biology research. The phospholipid provides structural integrity to lipid-based carriers and can modulate membrane properties.
|
| Enzyme Assay |
DPPG sodium liposome formation involves dissolving the phospholipid with other lipids in organic solvent, drying to form a lipid film, and hydrating with aqueous buffer. The resulting liposomes are extruded to achieve uniform size. Particle characterization includes dynamic light scattering for size and zeta potential measurements.
|
| Cell Assay |
Cellular assays for DPPG sodium are performed as part of liposome and drug delivery studies. Cells are treated with DPPG sodium-containing liposomes encapsulating therapeutic agents or fluorescent markers. Cellular uptake, cytotoxicity, and biological activity of encapsulated agents are assessed.
|
| Animal Protocol |
In vivo studies involve administration of DPPG sodium-containing liposomal formulations in rodent models. Pharmacokinetic parameters such as circulation half-life, tissue distribution, and therapeutic efficacy are evaluated. DPPG sodium is used in preclinical studies for drug delivery and membrane biology research.
|
| ADME/Pharmacokinetics |
As a phospholipid, DPPG sodium does not have conventional pharmacokinetic properties. When incorporated into liposomes, it contributes to the stability and circulation time of the formulation. The compound is metabolized through normal lipid metabolism pathways.
|
| Toxicity/Toxicokinetics |
DPPG sodium is a naturally occurring phospholipid and is generally considered biocompatible and low in toxicity. Standard safety precautions for handling lipids should be followed. No significant toxicity has been reported for the compound itself.
|
| References | |
| Additional Infomation |
DPPG sodium (MW: 744.95, Formula: C38H74NaO10P, purity ≥98%) is a phospholipid containing long-chain (16:0) palmitic acid. It is used to prepare micelles, liposomes, and other types of artificial membranes. DPPG sodium has been reported to inhibit cowpox virus infection as a surfactant.
|
| Molecular Formula |
C38H74NAO10P
|
|---|---|
| Molecular Weight |
744.95
|
| Exact Mass |
744.491
|
| CAS # |
200880-41-7
|
| Related CAS # |
DPPG-d62 sodium;326495-46-9
|
| PubChem CID |
46891827
|
| Appearance |
White to off-white solid powder
|
| LogP |
10.329
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
50
|
| Complexity |
804
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC(CO)O)OC(=O)CCCCCCCCCCCCCCC.[Na+]
|
| InChi Key |
LDWIWSHBGAIIMV-ODZMYOIVSA-M
|
| InChi Code |
InChI=1S/C38H75O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(41)45-33-36(34-47-49(43,44)46-32-35(40)31-39)48-38(42)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h35-36,39-40H,3-34H2,1-2H3,(H,43,44);/q;+1/p-1/t35?,36-;/m1./s1
|
| Chemical Name |
sodium;[(2R)-2,3-di(hexadecanoyloxy)propyl] 2,3-dihydroxypropyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 8.33 mg/mL (11.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3424 mL | 6.7119 mL | 13.4237 mL | |
| 5 mM | 0.2685 mL | 1.3424 mL | 2.6847 mL | |
| 10 mM | 0.1342 mL | 0.6712 mL | 1.3424 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
